Shares of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) have been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.

Brokers have set a 1-year consensus price target of $24.00 for the company and are forecasting that the company will post ($0.55) EPS for the current quarter, according to Zacks. Zacks has also given Aeglea BioTherapeutics an industry rank of 113 out of 265 based on the ratings given to its competitors.

Separately, Zacks Investment Research lowered Aeglea BioTherapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, September 19th.

ILLEGAL ACTIVITY WARNING: This news story was first posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at

Aeglea BioTherapeutics (AGLE) traded up $0.11 during mid-day trading on Thursday, reaching $4.65. The company’s stock had a trading volume of 59,700 shares, compared to its average volume of 65,762. Aeglea BioTherapeutics has a 12 month low of $2.81 and a 12 month high of $10.34.

Aeglea BioTherapeutics (NASDAQ:AGLE) last posted its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.07. The company had revenue of $1.26 million for the quarter. Aeglea BioTherapeutics had a negative return on equity of 44.05% and a negative net margin of 527.99%. equities research analysts anticipate that Aeglea BioTherapeutics will post -1.97 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp acquired a new position in Aeglea BioTherapeutics during the first quarter worth about $157,000. Renaissance Technologies LLC acquired a new position in Aeglea BioTherapeutics during the first quarter worth about $270,000. Vanguard Group Inc. grew its holdings in Aeglea BioTherapeutics by 9.4% during the second quarter. Vanguard Group Inc. now owns 150,774 shares of the biotechnology company’s stock worth $579,000 after acquiring an additional 12,966 shares during the period. Finally, Susquehanna International Group LLP acquired a new position in Aeglea BioTherapeutics during the second quarter worth about $653,000. 47.51% of the stock is currently owned by institutional investors.

About Aeglea BioTherapeutics

Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.

Get a free copy of the Zacks research report on Aeglea BioTherapeutics (AGLE)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Aeglea BioTherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.